Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zimmer Biomet Holdings, Inc. (NYSE: ZBH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zimmer Biomet is a global medical technology company focused on musculoskeletal health and orthopedic implants, and its filings offer detailed insight into its operations, capital structure, risk factors and governance.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Zimmer Biomet’s product categories such as knees, hips, sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T.), and technology and data, bone cement and surgical. These reports typically include segment and geographic sales information, descriptions of the company’s digital and robotic technologies, and management’s discussion and analysis.
You will also find current reports on Form 8-K covering material events, including quarterly earnings releases, new debt issuances, revolving credit agreements, acquisitions such as the merger with Monogram Technologies Inc., and other significant corporate developments. Filings describing the company’s notes and bonds, including series listed on the New York Stock Exchange, provide detail on interest rates, maturities, covenants and redemption features.
Stock Titan enhances these documents with AI-powered summaries that explain key points in clear language, helping users navigate complex topics like non-GAAP financial measures, leverage covenants and transaction structures. The platform also surfaces insider and executive-related filings, such as those reporting departures or appointments of certain officers, so users can track governance changes. With real-time updates from EDGAR and AI-generated highlights, this page is a focused resource for analyzing Zimmer Biomet’s SEC reporting history and ongoing regulatory disclosures.
Zimmer Biomet Holdings, Inc. furnished an 8-K announcing a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and its information is incorporated by reference in the report.
The Item 2.02 information, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings except by specific reference. An additional Exhibit 104 (Cover Page Interactive Data File) is included.
Zimmer Biomet Holdings (ZBH) reported an insider equity award on a Form 4. The company’s Executive Vice President and CFO received 10,632 restricted stock units (RSUs), recorded as an acquisition at $0 per unit and held directly.
The RSUs were part of a performance-based grant made on September 1, 2023, with results measured over October 1, 2024 to September 30, 2025. On October 24, 2025, the final outcome was determined, and 10,632 RSUs were earned. Each RSU represents the right to receive one share of Zimmer Biomet common stock. The earned RSUs are scheduled to vest on November 10, 2025.
Zimmer Biomet Holdings, Inc. completed its acquisition of Monogram Technologies Inc. through a merger on October 7, 2025, making Monogram a wholly owned subsidiary. At the merger’s effective time, each share of Monogram common stock was converted into the right to receive $4.04 in cash, without interest, plus one contractual contingent value right under a Contingent Value Rights Agreement with Computershare Trust Company, N.A. Each share of Monogram Series D preferred stock became entitled to $2.25 in cash, without interest, plus any accrued but unpaid dividends, and each share of Series E preferred stock became entitled to $100.00 in cash, without interest. The company also issued a press release on October 7, 2025 announcing the merger closing.
Devdatt Kurdikar, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 140.163 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The derivative units convert on a 1-for-1 basis into common stock and are scheduled to be settled in shares within sixty days after the director’s service ends. The report shows 1,613.887 shares of common stock beneficially owned following the reported transaction, and it notes 3.428 phantom units were added on 07/31/2025 via the plan’s dividend reinvestment provision.
Kolli Sreelakshmi, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 159.276 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The units convert 1-for-1 into common shares and are to be settled in company stock within sixty days after the director stops service. Following the transaction, the report shows beneficial ownership of 5,393.594 shares (including 13.119 units added via dividend reinvestment on 07/31/2025). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported an acquisition of 344.036 phantom stock units on 09/30/2025 under the companys Deferred Compensation Plan for Non-Employee Directors. The phantom units convert 1-for-1 into common stock value and are to be settled in cash in ten annual installments commencing within 60 days after the end of the calendar year in which her director service ends. The report notes 26.33 of the units were credited on 07/31/2025 via the plans dividend reinvestment provision. Following the transaction the filing shows total beneficial ownership of 10,875.718 shares.
Robert Hagemann, a non-employee director of Zimmer Biomet Holdings, Inc. (ZBH), was granted 280.326 phantom stock units on 09/30/2025 under the company's Deferred Compensation Plan for Non-Employee Directors. The units convert on a 1-for-1 basis into common stock value and are recorded at a per-unit price of $98.1, producing a reported aggregate value of $31,207.57. The filing notes that 79.18 of the units were accrued on 07/31/2025 under a dividend reinvestment provision. The phantom units are payable in cash in five annual installments beginning within 60 days after the calendar year in which the director's service ends.
Insider transaction disclosed for ZIMMER BIOMET HOLDINGS, INC. (ZBH). The reporting person, Sang Yi, Group President, Asia Pacific and an officer and director, reported a sale of 1,200 shares of common stock on 09/11/2025 at a price of $103.585 per share. After the sale, the filing shows 18,584 shares beneficially owned by the reporting person. The filing also notes that the reported beneficial ownership includes 160 shares acquired under the Employee Stock Purchase Plan on June 30, 2025. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Form 144 notice for Zimmer Biomet Holdings, Inc. (ZBH) shows a proposed sale of 1,200 common shares through Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $124,302.00. The filing reports 198,095,984 shares outstanding for the issuer and lists the planned exchange as the NYSE. The securities being offered were acquired by restricted stock vesting on 03/01/2024 (1,144 shares) and 03/06/2024 (56 shares), with payment characterized as compensation.
The filing also discloses prior sales by the same person, Sang Uk Yi, of 1,000 shares on 06/11/2025 for $95,000.00 and 800 shares on 06/13/2025 for $74,010.96. The signer certifies no undisclosed material adverse information and acknowledges the Rule 144 representation and criminal penalties for misstatements.
Lori Winkler, Senior Vice President and CHRO of Zimmer Biomet Holdings, reported sales of common stock on September 8, 2025. The Form 4 discloses 1,500 shares sold at a weighted average price of $104.15 per share (individual sale prices ranged from $104.15 to $104.18). After the transactions, Ms. Winkler beneficially owns 6,833 shares, held directly. The sale was reported on the Form 4 filed September 10, 2025, and was executed by an attorney-in-fact on her behalf.